Best-Practice Use of Bispecific Antibodies for Non-Hodgkin Lymphoma — A Second Opinion Case Review

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

MODULE 1: Bispecific Antibody Therapy for Diffuse Large B-Cell Lymphoma

MODULE 2: Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes

MODULE 3: Novel Bispecific Antibodies Undergoing Evaluation for Non-Hodgkin Lymphoma

MODULE 4: Tolerability Considerations with CD20 x CD3 Bispecific Antibodies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma (NHL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for various forms of NHL, and assess the similarities and differences among currently available agents in this class.
• Evaluate the available clinical research database with CD20 x CD3 bispecific antibodies in the management of diffuse large B-cell lymphoma (DLBCL), and optimally incorporate this approach into current treatment algorithms.
• Assess available research findings with CD20 x CD3 bispecific antibodies for follicular lymphoma (FL), and identify patients for whom this therapeutic modality should be considered and/or recommended.
• Evaluate published clinical research data with CD20 x CD3 bispecific antibodies in com-bination with other systemic therapies, and consider the current implications of these findings for DLBCL and FL management.
• Understand the biological rationale for and current clinical research database with investigational CD19 x CD3 bispecific antibodies in the management of NHL, and reflect on the ongoing evaluation and potential role of these agents.
• Recognize adverse events associated with available and investigational bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing research studies attempting to further define the optimal role of bispecific antibody-based strategies for NHL, and appropriately counsel patients regarding clinical trial participation.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
To be announced.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Genmab US Inc.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.